IMV Inc. is developing injectable cancer immune therapy using the company’s DPXTM technology. DPX is a patented formulation that displays excellent tumor control and provides a long lasting and specific effect. The way by which this therapy exerts its effect is unclear but the translational team at IMV is determined to discover its mechanism of action and why their proprietary DPX technology delivers superior responses in comparison to other forms of injectable therapies.
Cancer afflicts 1 in 8 people worldwide. Recent advancements in bench-to-bedside translational research has resulted in numerous effective treatments. However, a harsh reality still exists in that only ~20% of patients respond positively to treatment. Not all cancers are created equal, which has led to these clinical complexities undermining treatment options. It is our goal to understand the cellular and immune cell factors, which determine patient outcomes.